- Home
- ABUS vs IIIN Comparison
ABUS vs IIIN Comparison
Compare ABUS & IIIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- IIIN
- Stock Information
- Founded
- ABUS 2005
- IIIN 1953
- Country
- ABUS United States
- IIIN United States
- Employees
- ABUS N/A
- IIIN N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- IIIN Steel/Iron Ore
- Sector
- ABUS Health Care
- IIIN Industrials
- Exchange
- ABUS Nasdaq
- IIIN Nasdaq
- Market Cap
- ABUS 611.0M
- IIIN 704.8M
- IPO Year
- ABUS N/A
- IIIN N/A
- Fundamental
- Price
- ABUS $3.37
- IIIN $37.16
- Analyst Decision
- ABUS Strong Buy
- IIIN
- Analyst Count
- ABUS 3
- IIIN 0
- Target Price
- ABUS $5.67
- IIIN N/A
- AVG Volume (30 Days)
- ABUS 636.5K
- IIIN 130.9K
- Earning Date
- ABUS 08-06-2025
- IIIN 07-17-2025
- Dividend Yield
- ABUS N/A
- IIIN 3.01%
- EPS Growth
- ABUS N/A
- IIIN 53.01
- EPS
- ABUS N/A
- IIIN 1.59
- Revenue
- ABUS $15,416,000.00
- IIIN $604,566,000.00
- Revenue This Year
- ABUS $3.35
- IIIN $25.52
- Revenue Next Year
- ABUS N/A
- IIIN $10.03
- P/E Ratio
- ABUS N/A
- IIIN $23.39
- Revenue Growth
- ABUS 53.23
- IIIN 9.44
- 52 Week Low
- ABUS $2.71
- IIIN $22.49
- 52 Week High
- ABUS $4.73
- IIIN $41.64
- Technical
- Relative Strength Index (RSI)
- ABUS 54.05
- IIIN 53.45
- Support Level
- ABUS $3.33
- IIIN $34.67
- Resistance Level
- ABUS $3.45
- IIIN $38.04
- Average True Range (ATR)
- ABUS 0.12
- IIIN 0.84
- MACD
- ABUS 0.01
- IIIN 0.16
- Stochastic Oscillator
- ABUS 36.21
- IIIN 73.89
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
About IIIN Insteel Industries Inc.
Insteel Industries Inc manufactures steel wire reinforcing products for concrete construction applications. It manufactures and markets PC strand and welded wire reinforcement, including ESM, concrete pipe reinforcement, and standard welded wire reinforcement. The company's products are sold to manufacturers of concrete products that are used in nonresidential construction. Its concrete reinforcing products consist of two product lines: PC strand and WWR. Insteel generates its geographical revenue from the United States.